

Market Announcement



27 October 2026

Noxopharm Limited (ASX: NOX) – Trading Halt

Trading in the securities of Noxopharm Limited ('NOX') will be halted at the request of NOX, pending the release of an announcement by NOX.

Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of:

- the commencement of normal trading on Thursday, 29 October 2026; or
- the release of the announcement to the market.

NOX's request for a trading halt is attached below for the information of the market.

Issued by

ASX Supervision



27 October 2026

Trading Halt Request

ASX Limited
Listings Compliance, Sydney
Exchange Place
Level 27
39 Martin Place
Sydney NSW 2000

By email only: tradinghaltssydney@asx.com.au

Dear Manager

Noxopharm Limited [ASX:NOX] (**Company or Noxopharm**) hereby requests a trading halt in relation to the Company's Securities quoted on the Australian Securities Exchange (**ASX**) in accordance with ASX Listing Rule 17.1.

The trading halt is requested pending an announcement by the Company to the market regarding a material Capital Raising (**the Purpose**).

In accordance with ASX Listing Rule 17.1, the Company provides the following information in relation to the request:

- The trading halt is necessary to assist Noxopharm in managing its continuous disclosure obligations as the Company expects to make an announcement to the market in relation to the stated Purpose above.
- Noxopharm requests that the trading halt remain in place until the earlier of commencement of normal trading on Thursday, 29 October 2026, or when the announcement regarding the stated Purpose is released to the market.
- Noxopharm is not aware of any reason why the trading halt should not be granted or of any further information necessary to inform the market about the trading halt.

For and on behalf of the Board,

Shawn van Boheemen
Company Secretary

Investor, Corporate & Media enquiries:

Julian Elliott

M: 0425 840 071

E: julian.elliott@noxopharm.com

Gabriella Hold

The Capital Network

M: 0411 364 382

E: gaby@thecapitalnetwork.com.au

Company Secretary:

Shawn van Boheemen

T: +61 414 903 376

E: shawn.vanboheemen@noxopharm.com

About Noxopharm

Noxopharm Limited (ASX:NOX) is a clinical-stage Australian biotech company developing novel, targeted therapies for chronic inflammation, autoimmune diseases and cancer.

Noxopharm's proprietary Sofra™ platform is designed to regulate innate immune signalling with greater precision. Its lead clinical asset, SOF-SKN™, is a topical therapy initially being developed for cutaneous lupus erythematosus, with Phase I completed and further clinical development progressing.

Beyond SOF-SKN, the Sofra platform supports a broader pipeline of internal and externally collaborated programs across inflammatory and autoimmune diseases, RNA therapeutics and oncology.

To learn more, please visit: noxopharm.com

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as "aim", "anticipate", "assume", "believe", "continue", "could", "estimate", "expect", "intend", "may", "plan", "predict", "project", "plan", "should", "target", "will" or "would" or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company's control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.